Activation of PTGS2/NF-κB signaling pathway enhances radiation resistance of glioma

PTGS2/NF-κB信号通路激活增强胶质瘤放射抗性

阅读:14
作者:Cheng Tan, Liang Liu, Xiaoyang Liu, Ling Qi, Weiyao Wang, Guifang Zhao, Libo Wang, Yimeng Dai

Conclusion

PTGS2/NF-κB signaling pathway was involved in radio-tolerance of glioma cells, which provided a new insight into glioma therapy.

Methods

We downloaded the microarray data from the Gene Expression Omnibus (GEO) database. We verified transfection successfully through QRT-PCR analysis. Immunofluorescence was used to detect γH2AX content under 2 Gy radiation. The survival rates of cells under 2 Gy irradiation were tested by clonogenic survival assay. Flow cytometry was used to detect cell cycle. Western blot was applied to detect the expression of NF-κB pathway-related proteins. We also used MTT assay to detect the proliferation of cells.

Objective

We focused on the effects of PTGS2/NF-κB signaling pathway on the radiation resistance of glioma in the study.

Results

In this research, we discovered that the expression of the PTGS2 was upregulated in radiation-resistant glioma cells. The radio-tolerance rate of U87 cells was obviously elevated after the overexpression of PTGS2. The radioresistance of U87R cells was significantly reduced after the knockdown of PTGS2. After radiotherapy, the number of cells arrested in G2/M phase decreased after PTGS2 overexpression in U87cells but increased in PTGS2 knockdown in U87R cells. The survival rate of U87 and U87R cells under radiation decreased significantly after the addition of NF-κB inhibitor. The proliferation of U87 cells was suppressed by radiation and the addition of Bay 11. In addition, PTGS2 activated NF-κB signaling pathway and prevented DNA damage after radiotherapy. Lastly, PTGS2 was proved to facilitate tumor cell proliferation and improve the radio-tolerance.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。